Stockscreener 앱 받기
3.00
0.67%
0.02
시간 외 거래:
3.00
전일 마감가:
$2.98
열려 있는:
$2.98
하루 거래량:
802
Relative Volume:
0.10
시가총액:
$4.62M
수익:
$2.54M
순이익/손실:
$-4.13M
주가수익비율:
-1.0909
EPS:
-2.75
순현금흐름:
$-4.11M
1주 성능:
-1.50%
1개월 성능:
+4.90%
6개월 성능:
-29.58%
1년 성능:
-19.79%
1일 변동 폭
$2.8645
$3.00
1주일 범위
$2.83
$3.00
52주 변동 폭
$2.20
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
명칭
Xenetic Biosciences Inc
전화
781-778-7720
주소
945 CONCORD ST., FRAMINGHAM, MA
XBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.00 | 4.45M | 2.54M | -4.13M | -4.11M | -2.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-08 | 개시 | Maxim Group | Buy |
Xenetic Biosciences Inc 주식(XBIO)의 최신 뉴스
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post
Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire
Xenetic Biosciences, Inc. to Present at BIO Investor Forum - ACCESS Newswire
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire
Xenetic Biosciences Inc (XBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):